Cargando…
The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments
The International Prognostic Score (IPS) is the most commonly used risk stratification tool for patients with advanced Hodgkin lymphoma (HL). It incorporates seven clinical parameters independently associated with a poorer outcome: male sex, age, stage IV, hemoglobin level, white blood cell and lymp...
Autores principales: | Bari, Alessia, Marcheselli, Raffaella, Sacchi, Stefano, Re, Alessandro, Pagani, Chiara, Tucci, Alessandra, Botto, Barbara, Vitolo, Umberto, Molinari, Anna Lia, Puccini, Benedetta, Pulsoni, Alessandro, Santoro, Armando, Tani, Monica, Nassi, Luca, Meli, Erika, Pavone, Vincenzo, Bonfichi, Maurizio, Evangelista, Andrea, Gioia, Daniela, Levis, Alessandro, Zinzani, Pierluigi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6976582/ https://www.ncbi.nlm.nih.gov/pubmed/31872362 http://dx.doi.org/10.1007/s00277-019-03893-7 |
Ejemplares similares
-
Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial
por: Ricardi, Umberto, et al.
Publicado: (2021) -
Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience
por: Moretti, Marina, et al.
Publicado: (2022) -
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi
por: Gotti, Manuel, et al.
Publicado: (2023) -
Losing self control
por: Miller, Luke, et al.
Publicado: (2016) -
Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS
por: Stefoni, Vittorio, et al.
Publicado: (2020)